Refine by
Mitral Heart Valve Articles & Analysis
26 news found
MitraClip is a procedure that approximates the mitral valve leaflets thereby addressing an incompetent valve that is regurgitating, also known as “leaking.” Significant mitral regurgitation prevalence rates are estimated to be up to 10% to 25% in patients in their seventies. ...
InnovHeart s.r.l. announced today the appointment of David James Wilson, an experienced healthcare and medical device executive as Chief Executive Officer of the company and executive member of the Board of Directors. Mr. Wilson’s career spans over 30 years and includes broad, global leadership expertise in business strategy and operations, R&D, commercial readiness and product ...
” The reSept ASD Occluder aims to address the limitations of current occluders which have metallic frames that can place patients at risk of complications associated with long-term presence of metal in the heart and may limit future transseptal interventions, such as mitral valve interventions. ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its ...
I am pleased to say, that following IDE approval of the ALIGN-AR Trial in August 2021, patient enrollment remains on track as we diligently work to achieve our ultimate goal of receiving U.S. FDA approval for the Trilogy Heart Valve System.” “With the addition of the TrilogyTM, Peijia will have a more comprehensive product portfolio to better serve ...
BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, and the Montreal Heart Institute (MHI), a world-renowned, ultra-specialized cardiology center, announced they are partnering to develop a new cardiovascular training solution to help cardiologists rehearse and train for complex valve-in-valve ...
ByBIOMODEX
Phillip Chan, Chief Executive Officer of CytoSorbents, stated, “Today, infective endocarditis makes up a minor part of our overall usage and revenue in cardiac surgery and we believe that CytoSorb will continue to be used in selected infective endocarditis populations. For example, prosthetic heart valve endocarditis is associated with very high mortality ...
In addition, the Carillon Mitral Contour System can now be considered under the new Class IIb 2021 Guidelines for the Management of Valvular Heart Disease recommendations on indications for mitral valve intervention in chronic severe secondary mitral regurgitation. Both guidelines were recently published in the ...
Dr Meduri is a recognized leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees. ...
The EMPOWER Trial is evaluating the Carillon Mitral Contour System® for the treatment of heart failure patients with early-stage functional mitral regurgitation (FMR). ...
Here is our ultimate list, compiled from analyst reports, of private medtech companies to watch. 4C Medical 4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitral regurgitation (MR). It is the first transcatheter mitral regurgitation (MR) therapy that directly ...
BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27. The series titled “A Case Series of the BioTrace Medical Tempo ...
Both of the published meta-analyses were conducted from three prospective, core lab reviewed, CEC/DSMB adjudicated and third-party monitored clinical studies which enrolled a total of 209 heart failure patients with reduced ejection fraction and functional mitral regurgitation (FMR). ...
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert White as an independent director to its Board of Directors. ...
Valcare Medical Ltd. developer of transcatheter mitral and tricuspid valve repair and replacement solutions, announces that it has successfully completed its first-in-human transseptal delivery of the AMEND™ annuloplasty ring. ...
” An estimated 26 million people, worldwide, suffer from heart failure1 and of those, approximately 70 percent have functional mitral regurgitation. FMR is due to the mitral valve not closing tightly, resulting in blood flowing or leaking backwards through the mitral valve. ...
The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the primary cause of FMR in patients with mitral regurgitation grades 2+, 3+ and 4+. ...
Dr. von Bardeleben heads the Heart Valve Center and Center of Cardiology at the University of Mainz. ...
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of pooled prospectively collected data from three studies of the Carillon Mitral Contour System® with a focus on 5-year ...
The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the primary cause of FMR in patients with MR grades 2+, 3+ and 4+. “We know that mitral regurgitation in the context of heart failure is strongly associated with increased morbidity and mortality,” ...